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論    文    の    要    旨 
  
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), affects 
millions of patients worldwide.1 The intestinal mucosa of patients with IBD is characterized by reactive oxygen 
species (ROS) overproduction, leading to oxidative damage and imbalance in the constitution of intestinal 
microflora. Self-sustaining cycles of oxidant production may amplify inflammation and mucosal injury, 
promoting carcinogenesis.2  In several experimental models, antioxidant compounds and free radical scavengers 
have improved colitis and inhibited inflammation-associated cancer development.3 However, these 
low-molecular-weight (LMW) compounds are not completely effective due to a non-specific drug distribution, a 
low retention in the colon and severe adverse effects. If antioxidant compounds are specifically targeted to the 
diseased sites and effectively scavenge excessive generated ROS, they represent a safe and effective treatment 
for IBD. Nanoparticles such as liposome and polymeric micelles have gained worldwide attention as a new 
medical technology, because they change biodistribution of drugs to result in therapeutic effect of drugs 
significantly.4 Recently, we have developed an amphiphilic block copolymer, poly(ethylene 
glycol)-b-poly[p-4-(2,2,6,6-tetramethylpiperidine-1-oxyl)aminomethylstyrene] (MeO-PEG-b-PMNT), 
possessing stable nitroxide radicals in the hydrophobic segment as a side chain via an amine linkage, which 
forms core-shell-type micelles in the physiological environment with an average diameter of about 40 nm, and 
termed nitroxide radical-containing nanoparticle (RNPN).5 Nitroxide radicals are confined in the core of this 
micelle, which shows high biocompatibility, including long-term blood circulation when administered 
intravenously and low toxicity. Therefore, RNPN has been studied for therapy in oxidative stress injuries5-9 and 
bioimaging.10-11 For example, pH-sensitive RNPN works effectively in acute renal injury5 and cerebral 
ischemia-reperfusion6 because it disintegrates in acidic conditions of diseased area by protonation of amino 
groups. However, pH-disintegrative character is not suitable for the treatment of IBD via oral administration.  
In this study, a novel nanotherapy for the treatment of UC via oral administration is described. In order to 
target the nanoparticle to the colon area, its accumulation in the colonic mucosa is optimized, preventing its 
uptake into the bloodstream. A new designed redox polymer, methoxy-poly(ethylene 
glycol)-b-poly[p-4-(2,2,6,6-tetramethylpiperidine-1-oxyl)oxymethylstyrene] (MeO-PEG-b-PMOT), is an 
amphiphilic block copolymer with stable nitroxide radicals in a hydrophobic segment as a side chain via an ether 
linkage and forms 40-nm-diameter core-shell-type micelles (RNPO) by self-assembly in the aqueous 
environments regardless of pH . The objective of this study is to investigate the specific accumulation of RNPO 
in inflamed colon and its therapeutic effects on colitis and colitis-associated colon cancer (CAC) mice models 
via oral administration.  
The accumulation of nanoparticles in the colon area is one of the most important features for an effective 
nanomedicine against UC. In order to quantify the accumulation of nanoparticles in the colon area, we compared 
RNPO with different sizes of commercial available polystyrene latex particles and LMW TEMPOL. Because we 
introduced nitroxide radicals into the particles, their accumulation could be quantitatively monitored by ESR 
measurements. When we orally administered LMW TEMPOL to mice, almost no ESR signal was observed in 
the colon. In contrast, polystyrene latex particles showed a higher accumulation in the colon compared to LMW 
TEMPOL with the size-dependent accumulation. Polystyrene latex particles with 40 nm and 100 nm in size 
accumulated higher than large-sized particles (0.5 µm and 1 µm). Interestingly, when RNPO was administrated 
orally to mice, considerable high accumulation of RNPO in colon was observed, as compared to polystyrene 
latex particles, even though the same size (40 nm). High colloidal stability of RNPO due to the PEG tethered 
chains on the surface might be effective to accumulate in colonic mucosa as compared to polystyrene latex 
particles. In addition, the amount of accumulated RNPO in the colon of colitis mice was 50% higher than that in 
the normal colon under the same administration conditions. Furthermore, no internalization of RNPO in normal 
epithelial cells and no uptake of RNPO into bloodstream were observed. This is in sharp contrast to LMW 
TEMPOL, which was absorbed into the bloodstream through the GI tract in normal mice and even more in 
colitis mice.12 
Since orally administered RNPO accumulated in the colonic mucosa of DSS-injured mice and was not 
absorbed into the bloodstream, it is anticipated to be an ideal nanomedicine for UC treatment. Therefore, the 
therapeutic and suppressive effects of RNPO on dextran sodium sulfate (DSS)-induced colitis model mice were 
investigated. RNPO was orally administered daily to DSS-injured mice for 7 days. Additional DSS-injured mice 
were treated with LMW TEMPOL, commercially anti-ulcer mesalamine and micelle without nitroxide radicals as 
controls. After 7 days of treatment, the mice treated with DSS had a significant increase in disease activity index 
(DAI), pro-inflammatory cytokine and ROS levels as compared to control mice. The treatments with LMW 
TEMPOL or mesalamine showed efficiency to decrease DAI, cytokine and ROS levels as compared to 
DSS-treated mice, though this efficiency was not significant. On the contrary, RNPO-treated mice showed much 
lower inflammation compared to DSS-treated mice (P < 0.01) and other LMW drugs-treated mice. After 15 days 
of treatment, orally administered LMW TEMPOL and mesalamine slightly increased the survival rate (33.3% and 
50%, respectively) compared with DSS- and micelle-treated mice (16.7%). On the other hand, RNPO treatment 
significantly increased the survival rate of DSS-treated mice to 83.3%. These results indicate that RNPO has not 
only suppressive but also therapeutic effects on mice with DSS-induced colitis.12 
On the other hand, an imbalance in the constitution of intestinal microflora could lead to the dysregulation of 
host immunoreactivity towards intestinal bacteria, resulting in GI disorders and IBD.13 Therefore, the effect of 
RNPO on population of intestinal microflora was then evaluated. No remarkable differences in the total numbers 
of anaerobic and aerobic bacteria between experimental groups were observed during the DSS and RNPO 
treatments. The changes in number of E. coli and Staphylococcus sp., commensal bacteria related to colitis, were 
also observed during treatment with RNPO and DSS. The number of E. coli and Staphylococcus sp. significantly 
increases in DSS-treated mice, corresponding to the presence and severity of inflammation in colitis mice. In 
contrast, the number of these bacteria in mice treated with RNPO and DSS was significantly reduced compared 
to DSS-treated mice (P < 0.05).14 Importantly, the numbers of E. coli and Staphylococcus sp. in mice treated 
with RNPO alone were also similar to those of the control mice (104–106 CFU/g feces), indicating that oral 
administration of RNPO did not affect the growth of these commensal bacteria. These results indicate that RNPO 
did not affect at all to the microflora in normal mice and maintained the balance of microflora in colitis mice.14 
Because RNPO effectively suppressed the inflammation in colitis mice and did not disturb the intestinal 
microflora, the next challenge was to test the ability of RNPO to CAC model, which is colon cancer driven from 
inflammation. Azoxymethane (AOM) and DSS were used to chemically induced CAC in mice. After 70 days 
treatment, AOM/DSS-treated mice displayed a significant increase in tumor score. However, the mice given 5 
mg/mL RNPO for a month had significantly reduced tumor scores compared to AOM/DSS-treated mice. 
Interestingly, when anticancer drug Irinotecan (Iri) was administered in combination with free drinking RNPO, a 
remarkable suppression of tumor growth was observed in mice treated with combination compared to mice treated 
with Iri alone (P < 0.05). The Iri-induce adverse effects, such as diarrhea and GI toxicity, were remarkably reduced 
in RNPO-treated mice (P < 0.05). These results indicate that oral administration of RNPO not only significantly 
enhances the anticancer efficacy of Iri against CAC development, but also effectively suppresses the severe 
adverse effects of Iri.15 
Based on the obtained results in this study, it is concluded that RNPO is a very promising nanotherapeutics 
and drug delivery system for not only UC and CAC, but also other inflammation-associated diseases. 
 
 
References 
1. Khor B, Gardet A, Xavier RJ. Nat Rev 2011;474:307–317.  
2. Babbs CF. Free Radic Biol Med 1992;13:169–182. 
3. Ju J, Hao X, Lee MJ, et al. Cancer Prev Re 2009;2:143–152. 
4. Otsuka H, Nagasaki Y, Kataoka K. Adv Drug Deliv Rev 2003;55:403–419. 
5. Yoshitomi T, Hirayama A, Nagasaki Y. Biomaterials 2011;32:8021–8028. 
6. Marushima A, Suzuki K, Nagasaki Y, et al. Neurosurgery 2011;68:1418–1426. 
7. Chonpathompikunlert P, Yoshitomi T, Han J, et al. Ther Deliv 2011;2:585–597. 
8. Chonpathompikunlert P, Yoshitomi T, Han J, et al. Biomaterials 2011;32:8605–8612. 
9. Yoshitomi T, Nagasaki Y. Nanomedicine 2011;6:509–518. 
10. Yoshitomi T, Suzuki R, Mamiya T, et al. Bioconjugate Chem 2009;20:1792–1798. 
11. Yoshitomi T, Miyamoto D, Nagasaki Y. Biomacromolecules 2009;10:596–601. 
12. Vong LB, Tomita T, Yoshitomi T, Matsui H, Nagasaki Y. Gastroenterology 2012;143:1027–36. 
13. Sartor RB. Res Immunol. 1997;148:567–76. 
14. Vong LB, Yoshitomi T, Morikawa K, Saito S, Matsui H, Nagasaki Y. J Gastroenterol 2014;49:806–13. 
15. Vong LB, Yoshitomi T, Matsui H, Nagasaki Y. Biomaterials 2015, submitted.  
 審    査    の    要    旨 
〔批評〕 
  
論文審査及び質疑応答に関して、 
本論文は活性酸素種を安全に効果的に消去するナノ粒子を経口投与型治療薬として用い、
難治疾患で知られる潰瘍性大腸炎モデル、大腸バクテリアおよび大腸がん治療へと展開し
ている。材料合成、薬物動態、治療メカニズムの解析投稿範囲にわたる研究を行い、副作
用が無く、効果的に治療効果を出すことに成功した。このように本論文では新しい材料設
計と機能構築にわたる広範な成果を上げている点で評価された。  
 
〔最終試験結果〕 
 平成 27年 2月 19日、数理物質科学研究科学位論文審査委員会において審査委員の全員出席のもと、
著者に論文について説明を求め、関連事項につき質疑応答を行った。その結果、審査委員全員によっ
て、合格と判定された。 
 
〔結論〕 
 上記の論文審査ならびに最終試験の結果に基づき、著者は博士（工学）の学位を受けるに十分な資格
を有するものと認める。 
                                               
 
 
 
 
